Biotech | August 14, 2021
Bharat Biotech’s first nasal vaccine gets approval for Phase 2 trials
This is the first of its kind vaccine for Covid 19 to get the go-ahead
This is the first of its kind vaccine for Covid 19 to get the go-ahead
A treatment to prevent extreme symptoms and cut hospitalisation
Targeting KIT by frameshifting mRNA transcripts as a therapeutic strategy for aggressive mast cell neoplasm
The goal for the project is the identification and optimization of anti-viral compounds.
Single booster dose at 6 months of NVX-CoV2373 increased wild-type neutralizing antibodies more than 4-fold versus primary vaccination series
Nexviazyme specifically targets the M6P receptor, the key pathway for enzyme replacement therapy, to effectively clear glycogen build-up in muscle cells
By 2022, 150,000 primary health care centres would be in place in rural as well as urban areas
The transaction is expected to close in the Q4FY22
Whole-genome sequencing to identify genetic mutation; epidemiological studies to help assess the distribution and mathematical modelling to forecast spread
The company reported total income of Rs.1215.73 crores during the period ended June 30, 2021.
Subscribe To Our Newsletter & Stay Updated
